Business Context and Reporting Period
This Form 8-K Current Report was filed by Oncocyte Corporation (trading symbol: OCX) on June 6, 2023. The filing discloses the execution of an amended and restated employment agreement with Joshua Riggs, who serves as the Company's Chief Executive Officer. The agreement is effective as of May 1, 2023.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes and Executive Compensation
The primary material change disclosed is the formalization of Mr. Riggs' compensation package via the 2023 Employment Agreement. Key terms include:
- Base Salary: $360,000 per annum.
- Target Bonus: 50% of base salary.
- Equity Awards:
- CEO Grant: Options to purchase 350,000 shares. Vesting is 25% on the one-year anniversary, with the remainder vesting in 36 monthly installments thereafter.
- Performance Grant: Options to purchase 800,000 shares. Vesting is contingent on time and performance targets related to the 30-day volume-weighted average price of the Company's stock through December 31, 2025.
- Severance Provisions: In the event of termination without Cause or resignation for Good Reason, Mr. Riggs is entitled to 12 months of base salary, a pro-rated bonus, 12 months of health care premium reimbursement, and accelerated vesting of certain equity awards.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding business operations. The primary risk disclosed relates to the potential dilution of shareholders due to the grant of 1,150,000 stock options and the financial obligation of the severance package should the CEO's employment terminate under specific conditions.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2018 Equity Incentive Plan to assess the impact of the 1,150,000 new options granted to the CEO.
- Review the specific performance targets for the 800,000-share Performance Grant to understand the stock price thresholds required for vesting.
- Confirm the Company's current cash position to evaluate its ability to fund the potential 12-month severance obligation ($360,000) plus bonus and benefits if triggered.
- Check the exercise price of the new options, which is set to the fair market value on the grant date (third business day following June 6, 2023).